The Zhitong Finance app learned that Guangfa Securities published a research report stating that Yujinsuri Biotechnology (01548) had a “buy” rating with a reasonable value of HK$34.96. The company's traditional business is growing steadily, Carvykti's sales volume is highly certain in the next few years, and the company's performance is expected to maintain rapid growth.

The main views of GF Securities are as follows:

The company's underlying technical structure is rich, and Legendary Biotech is about to fulfill its growth potential.

Kingsley is moving towards diversification based on gene synthesis. Focusing on central rules and deep technology accumulation in the field of gene synthesis, the synergy between the four major business segments is obvious. The life science business is the company's cornerstone business, and at the same time, Legendary Biotech and Booming Biotech are expected to bring even stronger growth engines.

Legendary Creature - Expanded production capacity is waiting to be released, and Sidagio Orense is about to be released.

Continuing to promote the global clinical progress of Sidagiolense, at the ASCO conference, Cartitude-4 results showed that Clita-cel is expected to provide new treatment options for 2-4 line treatment. Legendary Biotech has submitted applications for expanded indications to the EMA and FDA, and is expected to continue to expand the scope of application in the future. Currently, the main factor limiting cell therapy volume is production capacity. Legendary Biotech is currently actively developing global production capacity, and the continued release of Cilta-Cel is expected to exceed expectations in the future.

The business sector develops collaboratively, and innovation drives continuous growth.

(1) Kingsley's life science business, segmenting racetrack leaders, and innovating to help sustainable development. (2) Booming biotechnology, abundant capital reserves, and low pressure on fixed assets, is expected to achieve steady revenue growth in the next three years. (3) Baisjie, based on industrial enzymes, is embarking on a new journey in synthetic biology.